Unknown

Dataset Information

0

Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation.


ABSTRACT: Background:While all clinically translated antibody-drug conjugates (ADCs) contain a single-drug payload, most systemic cancer chemotherapies involve use of a combination of drugs. These regimens improve treatment outcomes and slow development of drug resistance. We here report the generation of an ADC with a dual-drug payload that combines two distinct mechanisms of action. Methods:Virtual DNA crosslinking agent PNU-159682 and tubulin polymerization inhibitor monomethyl auristatin F (MMAF) were conjugated to a HER2-targeting antibody via site-specific conjugation at engineered selenocysteine and cysteine residues (thio-selenomab). Results:The dual-drug ADC showed selective and potent cytotoxicity against HER2-expressing cell lines and exhibited dual mechanisms of action consistent with the attached drugs. While PNU-159682 caused S-phase cell cycle arrest due to its DNA-damaging activity, MMAF simultaneously inhibited tubulin polymerization and caused G2/M-phase cell cycle arrest. Conclusion:The thio-selenomab platform enables the assembly of dual-drug ADCs with two distinct mechanisms of action.

SUBMITTER: Nilchan N 

PROVIDER: S-EPMC6953743 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4839195 | biostudies-literature
| S-EPMC8308878 | biostudies-literature
| S-EPMC10153793 | biostudies-literature
| S-EPMC7555909 | biostudies-literature
| S-EPMC6906777 | biostudies-literature
| S-EPMC4331128 | biostudies-literature
| S-EPMC7898269 | biostudies-literature
| S-EPMC7906296 | biostudies-literature
| S-EPMC5910183 | biostudies-literature
| S-EPMC4651790 | biostudies-literature